Drug Regulators EMEA, Publish Guidance on Clinical Investigations of Medicinal Products Intended for the Treatment of Glucocorticoid-Induced Osteoporosis

Full Text Here

Oral glucocorticoid therapy is widely used for the treatment of a variety of diseases. Approximately 1% of the population is prescribed oral glucocorticoids, and in the elderly this prevalence rises to 2.5% . The association between glucocorticoid therapy and osteoporosis is well documented and exhibits some characteristic features. Bone loss is particularly rapid in the first few months after initiation of therapy, with a slower rate of loss subsequently. Fracture risk also increases rapidly during the early months of therapy and declines after its cessation. Both cortical and cancellous bone are affected, and there is some reversibility of bone loss after cessation or reduction of therapy.
Although the severity of osteoporosis is related to the dose and duration of glucocorticoid therapy, some increase in fracture risk is seen even at daily doses of ≤7.5 mg daily for 3–6 months. Finally, the effect of glucocorticoids on bone fragility is, to some extent, independent of bone mineral density, fractures occurring at a higher bone mineral density (BMD) threshold than in postmenopausal osteoporosis (PMO). Glucocorticoid-induced osteoporosis (GIOP) and PMO share a number of characteristics with respect
to the cellular pathophysiology of bone loss. Increased bone turnover occurs in both conditions, but differs in its time course. In GIOP, an early and transient increase in bone turnover occurs against a background of low bone turnover with reduced bone formation at both tissue and cellular levels. The early increase in bone turnover in GIOP is likely to be a major contributor to bone loss and increased fracture risk within the first few months of initiating therapy and is therefore an important therapeutic target. In PMO, increased bone turnover is consistently observed over time. Both GIOP and PMO are associated with a reduction in bone formation at the cellular level, this effect
being quantitatively greater in GIOP than PMO and associated with a reduction in bone formation at the tissue level. Similar effects on cancellous bone microarchitecture have also been reported in the two conditions, depending on the dose of glucocorticoids used.

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulattions, rules and initiatives each month, and summarise them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”